Filing marks milestone for Eisai's oncology R&D
This article was originally published in Scrip
Eisai has made an approval filing in Switzerland for its novel anticancer agent eribulin mesylate (E7389), marking the first submission for an oncology agent developed in-house by the Japanese firm.
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.